New drug combination offers #ovarian #cancer breakthrough

📌 The phase 2 trial, led by the Royal Marsden NHS Foundation Trust and the Institute of Cancer Research (London) tested the drug #avutometinib alone and in combination with #defactinib in 29 patients.

📌 Trial results show almost half the patients on the new drug combination(45%) saw their tumours shrink significantly, almost twice as effective as the next best treatment – trametinib (response rate of 26%)

https://www.theguardian.com/science/2023/jun/03/new-drug-combination-offers-ovarian-cancer-breakthrough